Clinical Trials Directory

Trials / Terminated

TerminatedNCT01674010

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
309 (actual)
Sponsor
OPKO Health, Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.

Conditions

Interventions

TypeNameDescription
DRUGELND005
DRUGLamotrigine
DRUGValproic acid
DRUGPlacebo

Timeline

Start date
2012-08-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2012-08-28
Last updated
2019-10-21
Results posted
2015-10-12

Locations

82 sites across 9 countries: United States, Bulgaria, Canada, Czechia, France, Poland, Romania, Spain, Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT01674010. Inclusion in this directory is not an endorsement.